SCHEMBL4345929

SCHEMBL4345929

O=C(Nc1ccccc1C(F)(F)F)N(S)c1cc(Br)cc(F)c1O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 5/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
KDM4E B2RXH2 4/20 0.39
POLB P06746 3/20 0.39
TSHR P16473 1/20 0.39
GAA P10253 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
HTT P42858 1/20 0.38
MAPK1 P28482 1/20 0.38
GRIK1 P39086 1/20 0.37
THRB P10828 1/20 0.37
NOX1 Q9Y5S8 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4353761 0.84 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1TRPV1MEN1KMT2A
SCHEMBL4349655 0.82 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1L3MBTL1TRPV1MEN1
SCHEMBL4360059 0.81 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1TRPV1MEN1KMT2A
SCHEMBL4348538 0.80 NPC1 (0.47) SMN1; SMN2ALDH1A1MEN1KMT2ANPC1
SCHEMBL4349028 0.80 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1L3MBTL1TRPV1MEN1
SCHEMBL4347517 0.79 GRIK1 (0.45) SMN1; SMN2TRPV1MEN1KMT2AKDM4E
SCHEMBL4357779 0.79 HTT (0.43) SMN1; SMN2ALDH1A1TRPV1MEN1KMT2A
SCHEMBL4348981 0.79 EPHX2 (0.43) SMN1; SMN2ALDH1A1TRPV1MEN1KMT2A
SCHEMBL4342177 0.77 TRPV1 (0.50) SMN1; SMN2ALDH1A1TRPV1MEN1KMT2A
SCHEMBL4346890 0.76 KMT2A (0.43) SMN1; SMN2ALDH1A1TRPV1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 SMN1; SMN2 1791/4885ALDH1A1 2565/4885L3MBTL1 1972/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 SMN1; SMN2 3250/4885ALDH1A1 2767/4885L3MBTL1 2528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.